172 related articles for article (PubMed ID: 24034061)
41. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
42. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
[TBL] [Abstract][Full Text] [Related]
43. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
44. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients.
Noterdaeme T; Longrée L; Bataille C; Deroover A; Lamproye A; Delwaide J; Beguin Y; Honoré P; Detry O
World J Gastroenterol; 2011 Jul; 17(25):3069-72. PubMed ID: 21799656
[TBL] [Abstract][Full Text] [Related]
45. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
46. [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
Ono K; Iyama S; Matsunaga T; Sato T; Sato Y; Okuda T; Takada K; Kawano Y; Hayashi T; Miyanishi K; Sagawa T; Kobune M; Takimoto R; Kato J; Niitsu Y
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1509-12. PubMed ID: 17876158
[TBL] [Abstract][Full Text] [Related]
47. Immunosuppression and HBV reactivation.
Shouval D; Shibolet O
Semin Liver Dis; 2013 May; 33(2):167-77. PubMed ID: 23749673
[TBL] [Abstract][Full Text] [Related]
48. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
Pei SN; Chen CH; Lee CM; Wang MC; Ma MC; Hu TH; Kuo CY
Ann Hematol; 2010 Mar; 89(3):255-62. PubMed ID: 19697028
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
50. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
51. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
Pei SN; Chen CH
Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
Liu WP; Wang XP; Zheng W; Ping LY; Zhang C; Wang GQ; Song YQ; Zhu J
Leuk Lymphoma; 2016; 57(6):1355-62. PubMed ID: 26727044
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
54. [Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation].
Zheng S; Wu J; Wang W; Huang D; Liang T; Lu A
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):445-8. PubMed ID: 12133511
[TBL] [Abstract][Full Text] [Related]
55. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers.
Chen GD; Gu JL; Qiu J; Chen LZ
Transpl Infect Dis; 2013 Jun; 15(3):300-5. PubMed ID: 23473005
[TBL] [Abstract][Full Text] [Related]
56. Liver transplantation in lymphoma patients with hepatitis B virus reactivation.
Kim JM; Kwon CH; Joh JW; Ko SW; Park JB; Kim SJ; Lee JH; Kim GS; Kim SJ; Lee SK
Transplant Proc; 2013 Oct; 45(8):2988-91. PubMed ID: 24157019
[TBL] [Abstract][Full Text] [Related]
57. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
[TBL] [Abstract][Full Text] [Related]
60. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy.
Castelli R; Ferraris L; Pantaleo G; Lambertenghi Deliliers G; Cicardi M
Dig Liver Dis; 2016 Nov; 48(11):1394-1397. PubMed ID: 27590841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
